Abbvie (ABBV) PT Raised to $180 at Cowen as CD20xCD3 Has 'Best-In-Class' Potential
Tweet Send to a Friend
Cowen analyst Steve Scala raised the price target on Abbvie (NYSE: ABBV) to $180.00 (from $150.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
